Kornimate/medical-research-clean huggingface dataset:
effect of vibro-oscillatory therapy for improvement of body contour and appearance of cellulite.

Conditions: Body Fat Distribution; Cellulitis

Summary: objective: to evaluate the efficacy of vibro-oscillatory therapy through an electromedical equipment in improving body contour and appearance of cellulite. subjects and methods: a prospective and comparative longitudinal clinical study will be performed in 30 women with cellulitis. patients will be submitted to data collection and evaluation and before and after vibration-oscillatory therapy. hypotheses: patients are expected to show improvement in body contour and cellulite after vibration-oscillatory therapy. statistical analysis: a descriptive analysis will be done before and after vibration-oscillatory therapy, with frequency tables for categorical and descriptive variables (mean, standard deviation, median, minimum and maximum values) for continuous or numerical variables. in order to compare the main variables between the groups and the collection times, the analysis of variance (anova) for repeated measures will be used. tukey's test will be used to compare the groups. the significance level adopted for the statistical tests will be 5% or p \<0.05.

after approval by the institutional committee of research ethics, the subjects will be approached by the researcher responsible on the day of their evaluation, where they completed the registration form, after a brief analysis of the inclusion and exclusion criteria of the present study, the individuals included in the study will be collection of anthropometric data: weight, height, bmi, perimeter of the treated region, assessment of the degree of gynoid lipodystrophy, clinical inspection and photographic study of the treated area, ultrasound examination to assess the thickness of the dermis and hypodermis and the examination with cutometer ® to assess the viscoelasticity of the skin. patients will be divided according to the degree of cellulite they present and will be treated with vibration therapy, such as the modellata® electromedical equipment (ibramed- brazilian industry of electronic equipment), being performed three times a week for two months totaling 16 sessions by a dermato-functional physiotherapist. data collection and evaluation will be performed before and after treatment.

Eligibility criteria:
inclusion criteria: * female gender, over 18 years of age; * with body mass index considered eutrophic; * cellulite carriers; * non smokers; * that they agree to participate and sign the tcle. exclusion criteria: * male gender; * menopausal women; * have undergone aesthetic treatment in the gluteal region and thighs in the last 6 months; * patients with skin lesions, such as dermatitis and dermatoses; * patients with capillary fragility; * patients with acute deep vein thrombosis (dvt); * on or near cancerous lesions; * patients with cardiac pacemaker or other implanted electronic device
effects of epidural anesthesia and analgesia on the prognosis in patients undergoing pancreatic cancer surgery

Conditions: Cancer of Pancreas

Summary: the purpose of this randomized controlled trial is to investigate the effects of epidural anesthesia and analgesia on the overall survival，disease-free survival and recovery in patients undergoing pancreatic cancer surgery. this study will also evaluate the effects of this technique on neuroendocrine, stress and inflammatory response in these patients.


Eligibility criteria:
inclusion criteria: 1. undergoing elective pancreaticoduodenectomy for pancreatic cancer . 2. asa statusⅰ-ⅲ. 3. 18 years to 80 years （adults）. 4. able to understand, communicate and sign an informed consent form. exclusion criteria: 1. laparoscopic surgery. 2. preoperative chemotherapy or radiotherapy. 3. pregnancy. 4. allergic to any drugs used during the study. 5. long-term receiving β-blockers. 6. complicated with chronic inflammatory diseases, autoimmune diseases, or long-term receiving glucocorticoids or other immunosuppressants before surgery. 7. abnormal coagulation functions (platelet count prior to surgery \ 1.3 or clopidogrel that cannot be discontinued 7 days prior to surgery). 8. complicated with severe heart disease (nyha classification \>3), severe renal insufficiency (serum creatinine \>1.8mg/dl or receiving renal replacement therapy), severe hepatic disease (child-pugh classification = c), diabetes (fasting blood glucose not in the range of 3.9-13.8 mmol/l ), or acute infectious diseases (wbc\>10000/μl) before surgery. 9. bmi \> 35. 10. all contraindications to epidural anesthesia and analgesia. 11. chronic opiate medication/drug abuse. 12. complicated with severe mental illness, cognitive disorder or unable to collaborate during the study. 13. refuse to sign an informed consent form.
ultrasound guided thoracic paravertebral block for hepatic tumors ablation

Conditions: Liver Cancer

Summary: patients undergo percutaneous radiofrequency ablation of hepatic tumors at siriraj hospital normally receive only intravenous sedative drugs which sometimes can not provide effective pain control. tpvb is suitable for unilateral operations. and it is increasing popular nowadays because of using ultrasound guided which make it is more reliable and has less side effects especially the severe one such as pneumothorax. to cover all nerve supply liver, we decided to use right tpvb at t5-6, t7-8, and t9-10. the aim of this study is to prove that tpvb can provide an effective pain control for patients undergo liver rfa both at rest and movement (cough). we are going to measure the pain score at recovery room and the effective pain control means patients has mild pain (pain score less \</= 3 and do not ask for analgesic drugs).


Eligibility criteria:
inclusion criteria: * age \> 18 years * patients undergo percutaneous radiofrequency ablation for liver tumors * asa classification 1-3 exclusion criteria: * psychiatric illness * chronic abdominal pain \> 1 week * regular analgesic drugs use * infection at back (block area) * severe spinal deformity * pt \> 16 sec, aptt \> 32, platelet \< 50,000/cumm

Keywords: paravertebral block ultrasound guided
schizophrenia study in adults

Conditions: Schizophrenia

Summary: a placebo controlled study for patients with schizophrenia


Eligibility criteria:
inclusion criteria: * patient must meet diagnostic criteria for schizophrenia. exclusion criteria: * patients with other psychotic disorders. * patients whose condition is due to the direct physiological effects of a substances (e.g., drug abuse) or a general medical condition. * patients with a history of autistic disorder or another pervasive developmental disorder. * patients with epilepsy or a history of seizures requiring treatment. * patients who are excluded from taking the drug risperidone. * patients who pose a current serious suicidal or homicidal risk. * patients who are adequately stabilized on their treatment.

Keywords: talnetant schizophrenia nk3 receptor antagonist psychosis
influence of dha-rich supplement on dha-status and health evolution of patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: investigation of the influence of giving dha-rich supplement versus placebo on dha-status and health evolution of patients with cystic fibrosis

investigation of the influence of giving dha-rich supplement versus placebo on dha-status and health evolution of patients with cystic fibrosis

Eligibility criteria:
inclusion criteria: * delta f 508 homozygote * stable clinical situation exclusion criteria: -
metformin experience on minimal hepatic encephalopathy

Conditions: Liver Cirrhosis; Hepatic Encephalopathy

Summary: primary aim: -to assess the effect of metformin use on the treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. secondary aim: -to evaluate if metformin is a safety drug in patients showing liver cirrhosis.

in this study, 30 patients will be included divided in two arms. investigators and patients will not know the treatment used (double blind). arm 1: metformin 1000mg twice a day (2000 mg/day), during 12 weeks. arm 2: placebo 1000mg twice a day (2000mg/day), during 12 weeks. at the end of the study, patients will be followed-up 8 weeks more to control the appearance of adverse effects.

Eligibility criteria:
inclusion criteria: * patients with \> 18 years old * patients with the results of all the factors evaluable at the time of inclusion * patients who have accepted their participation in the study through informed consent * patients showing liver cirrhosis by ultrasound, transient elastography or liver biopsy * patients showing minimal hepatic encephalopathy (phes \< 4 or critical flicker frequency \< 39 hz) exclusion criteria: * patients with any contraindications to the drugs used * patients showing type 1 diabetes mellitus * patients showing type 2 diabetes mellitus and previous or current use of exogenous insulin, metformin or other oral antidiabetic drug

Keywords: hepatic encephalopathy metformin liver cirrhosis
opioid-induced bowel dysfunction: pivotal assessment of lubiprostone

Conditions: Opioid-Induced Bowel Dysfunction

Summary: the primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with opioid-induced bowel dysfunction.


Eligibility criteria:
inclusion criteria: * consistent treatment for chronic, non-cancer-related pain with any full agonist opioid for at least 30 days prior to screening. * diagnosis of opioid-induced bowel dysfunction (obd) as confirmed during the screening period. * if patient has a history of chronic constipation, condition must have been exacerbated by initiation of opioid treatment. * use of prescribed or over-the-counter (otc) medication that affects gastrointestinal motility (other than opioid therapy) must be discontinued during the study. * if treated for clinical depression with selective serotonin reuptake inhibitor (ssris), serotonin-norepinephrine reuptake inhibitor (snris), or monoamine oxidase inhibitor (mao) inhibitors, treatment must have been at a stable dose for at least 30 days prior to screening. * use of laxative and stool softeners (with the exception of approved rescue medications) must be discontinued while on study. exclusion criteria: * treatment with opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction. * patient has been treated for cancer in the past 5 years (with the exception of localized basal cell, squamous cell skin cancer, or in situ cancer that has been resected). * opioid dose adjustment (+/- 30%), and/or change in opioid agent or route of administration within 30 days of screening. * gastrointestinal or abdominal surgical procedures within 90 days prior to screening. * non-ambulatory patients, or those who are unable to eat/drink, take oral medications, or to hold down oral medications due to vomiting. * female patients of childbearing potential who are unable/unwilling to use protocol-specified method(s) of birth control and/or are pregnant, nursing, or plan to become pregnant or nurse during the study. * prior use of amitiza, lubiprostone, spi-0211, or ru-0211.
integrated alcohol and sexual assault prevention for bisexual women

Conditions: Alcohol Use, Unspecified; Sexual Assault

Summary: the goal of this clinical trial is to develop and evaluate the preliminary efficacy of an intervention to address reducing alcohol use, sexual revictimization, and psychological distress among bisexual+ women (i.e., attraction to more than one gender: bisexual, pansexual, queer). the main questions the study seeks to answer are: 1) what is the feasibility of the recruitment method, research design, interventionist training methods, and delivery of the intervention; 2) does the intervention, relative to control, at the 2- and 4-month follow-up period, produce reductions in the quantity and frequency of alcohol use, sexual victimization, and psychological distress (anxiety, depression). follow-up assessments are completed at 2- and 4-months following program completion. the intervention is compared to a wait list control group.


Eligibility criteria:
inclusion criteria: * be between the ages of 18 and 24 years of age; * identify as female gender or fluid, or gender non-conforming, gender queer, or non-binary * identify as bisexual+ (i.e., attraction to more than one gender: bisexual, pansexual, queer); * report a history of attempted or completed penetrative acts of sexual victimization (i.e., oral, vaginal, anal) since age 14 via coercion, incapacitation or force; * report exceeding the national recommended limits for daily drinking (4 or more for women) on two or more occasions in the past month; * report past month sexual activity. exclusion criteria: * current suicide risk on the beck depression inventory * current symptoms of alcohol use withdrawal on the alcohol use withdrawal checklist
time prediction and cerebellum: magnetic transcranial stimulation (tms) in healthy volunteers

Conditions: Schizophrenia

Summary: the aim of the study is to check the role of the cerebellum in time prediction in healthy volunteers, by means of magnetic transcranial stimulation targeted on the cerebellum, and recording of behavioural measures indexing time prediction


Eligibility criteria:
inclusion criteria: * participant, male or female, between 18 and 60 years old * subject affiliated to a social health insurance scheme (beneficiary or entitled person) * subject who has dated and signed an informed consent form * for a woman of childbearing age, negative pregnancy test and effective contraception throughout the study exclusion criteria: * - participant with substance use disorders (as defined by dsm-v) * participants taking benzodiazepines and related substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months before inclusion) or hallucinogenic substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product). * participant with neurological pathology or sequelae * participant with attention deficit hyperactivity disorder (adhd) * participant with a borderline personality disorder * participant with disabling sensory impairments, including visual acuity (corrected, if applicable) \< 0.8 (due to use of visual material) (freiburg vision test, bach 1996) * participant deprived of liberty or subject to the safeguard of justice * participant under guardianship or curatorship * participant in a period of exclusion defined by another clinical study or participant in a study that may impact on research results * pregnant or breastfeeding woman * subject with a contraindication to performing an mri or tms: presence of non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular lead, certain intracerebral clips, cochlear implants, history of epilepsy, skin pathology at the point of contact with the electrodes. * subject with a history of major neurological or psychiatric illness with current psychotropic medication (i.e., antidepressant, thyroid regulator, antipsychotic, benzodiazepine and related drugs, or hypnotic).
vaginal cuff dehiscence and thermal injury during tlh

Conditions: Vaginal Cuff Dehiscence; Thermal Injury

Summary: purpose of this randomized control study is to determine if the mode of electrothermal colpotomy incision affects (1) the degree of thermal injury at the time of laparoscopic hysterectomy or (2) the incidence of clinical surrogates of compromised vaginal cuff healing. women already scheduled for tlh will be randomized to colpotomy incision with the v mode or standard cut/coag form of electrothermal energy. prevalence of vaginal cuff injury will be calculated, and cross tabulation tables will be used to examine the association fo dehiscence with proposed risk factors in the retrospective part of the study. in the randomized controlled trial, depth of thermal injury will be compared between the two groups, and a chi-square test will be used to test for a difference in clinical outcomes between the two groups. there is little risk associated with this study above the normal surgical risks; however, the v mode has not been previously been studied for its use in making a colpotomy incision. loss of confidentiality is a risk of the study, but all samples will be de-identified and given a unique study number, and only individuals directly involved in the study will be given access to the study information.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. patient scheduled for total laparoscopic hysterectomy (tlh) 3. signed informed consent exclusion criteria: 1. known pelvic infection within 30 days prior to hysterectomy

Keywords: vaginal cuff dehiscence thermal injury total laparoscopic hysterectomy
genetic study of patients and families with diaphyseal medullary stenosis with malignant fibrous histiocytoma of the bone

Conditions: Stenosis; Histiocytoma

Summary: objectives: i. identify and characterize the gene causing diaphyseal medullary stenosis with malignant fibrous histiocytoma of the bone. ii. determine the clinical manifestations of this disease in these patients.

protocol outline: blood samples are obtained from affected individuals and their family members after genetic counseling. genetic linkage analysis is performed on these blood samples. unaffected individuals undergo x-rays and technetium bone scans to detect the presence of bone disease. affected individuals undergo bone densitometry, mri studies, thallium scans, ophthalmologic examination, electrocardiogram, echocardiogram, and skin biopsies. affected family members identified after radiologic studies receive additional genetic counseling.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- diagnosis of diaphyseal medullary stenosis with malignant fibrous histiocytoma of the bone or family member, including spouses, of an affected individual --patient characteristics-- renal: not specified * not pregnant * negative pregnancy test * no diminished mental capacity * no prisoners

Keywords: arthritis & connective tissue diseases bone cancer diaphyseal medullary stenosis genetic diseases and dysmorphic syndromes malignant fibrous histiocytoma of bone musculoskeletal/mesodermal cancer oncologic disorders rare disease
assay for the pancreatic polypeptide: an help for clinical practice guidelines in classification of the diabetes

Conditions: Type1diabetes

Summary: the purpose of this study is to evaluate global endocrine function within type 1 and type 3c diabetic patients, helping pancreatic polypeptide measurement.

all diabetes are the result of endrocrine deficiency. the endocrine deficiency may be absolute, as in type 1 diabetes, considered as an elective and exclusive attack of pancreatic beta cell, or it could be relative, as un type 2 diabetes. more rarely, diabetes fit into a broader context of pancreatic failure, with diffuse involvement of the exocrine and endocrine function, suggesting an impairment of the whole endocrine secretion of the pancreas, affecting the entire islet of langerhans, such as in type 3c diabetes, whose prototypes are total pancreatectomy, chronic alcoholic pancreatitis, cystic fibrosis. the diagnostic of type 3c diabetes is not always obvious, with several clinical presentations, without biological specific disease tag. moreover, it also appears that the common form of diabetes, type 1 and type 2, may be associated with an exocrine function deficit and with a decrease of the pancreatic volume correlated with exocrine function abnormalities, and a decrease of insulin secretion capacity. the consequences of a spread of the disease beyond the beta cells remain uncertain, but they could be linked, as in type 3c diabetes, with severe form of hypoglycaemia, due to glucagon deficiency, or nutritional deficiency due to the exocrine deficiency. the pancreatic polypeptide belongs to the neuropeptide y family, it is produced by the endocrine pancreatic f cells, located in the hook and the head of the pancreas. food intake stimulates its secretion. the role of the pancreatic polypeptide in human is uncertain. investigators propose to study the pancreatic polypeptide in type 1 and type 3c diabetes before and after a mixed meal in order to study the other endocrine functions of the islet of langerhans, to evaluate the possibility, or not, of a more diffuse pancreatic involvement in type 1 diabetes, considered as an elective pathology of the pancreatic beta cell.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older * patients with type 1 diabetes with anti-gad and / or ia2 and / or znt8 positive antibodies, or characteristic clinical history, with and without exocrine deficiency (\*) * patients with chronic alcoholic pancreatitis or cystic fibrosis origin (type 3c diabetes), complicated with diabetes defined by hba1c\> 6.5% or treated with oral anti-diabetic and / or insulin * patients who have given informed and written consent to participate in research * patients affiliated to a social security scheme (\*): the exocrine deficiency is defined by an assay of fecal elastase: * without deficit of exocrine function = fecal elastase = /\> 100 μg / g * with deficit of exocrine function = fecal elastase \<100 μg / g exclusion criteria: * pregnancy * severe renal impairment (edfg \<45 ml / min / 1.73 m²)

Keywords: pancreatic polypeptide type 1 diabetes chronic pancreatitis